>

Dov Hershberg - COMPUGEN Director

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:4em;padding-top: 25px;;'>CO</div>
CGEN -- Israel Stock  

ILA 2,573  181.00  6.57%

  Director
Mr. Dov Hershberg serves as Director of Compugen Ltd. prior to which he served as a consultant to the Board of Directors. From February 2009 through February 2010, Mr. Hershberg served as Chairman of the Board of Directors. Mr. Hershberg previously managed the BIRD Foundation from 1997 through 2006. Mr. Hershberg is a founder and a former CEO, management team and board member of Powermat Technologies Ltd., a wireless electricity company. Prior to joining the BIRD Foundation, Mr. Hershberg held various senior management positions in software development, marketing and sales. He was the founder and CEO, with colleagues from Stanford University, of Molecular Applications Group which created software in biomedical research. Mr. Hershberg spent eleven years at Digital Equipment Corporationrationration in various senior management positions in product development, marketing and sales and worked as a mathematician in the Israeli Aircraft Industry. Mr. Hershberg holds graduate degrees in Mathematics, from the Hebrew University in Jerusalem, Israel and in Applied Mathematics and Operations Research from Columbia University in New York City.
Age: 74  Director Since 2010      
(972) 3 765 8555  www.cgen.com

Management Efficiency

The company has return on total asset (ROA) of (0.01) % which means that it has lost $0.01 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (0.84) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 4.94 M in total debt with debt to equity ratio (D/E) of 14.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. COMPUGEN has Current Ratio of 7.05 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Itai CohenSOLEGREEN LTD
2017
Nir PelegSOLEGREEN LTD
2017
Estery GilozRanKAMADA
2014
Lea BloomEVOGENE LTD
2010
Abraham MeizlerKADIMASTEM
2014
Kinneret SavitzkyEVOGENE LTD
2010
Ran TzrorKITOV PHARMA LTD
2017
Simcha SadanEVOGENE LTD
2006
Shmuel PinchasSOLEGREEN LTD
2010
Michel RevelKADIMASTEM
2010
Avner NavehSOLEGREEN LTD
Abraham HavronKAMADA
2011
Adina MakoverEVOGENE LTD
2003
Ehood NisanSOLEGREEN LTD
2016
Reuven BeharKAMADA
2013
Revital SternRaffKITOV PHARMA LTD
2017
Simcha RockKITOV PHARMA LTD
2018
Aharon SchwartzPROTALIX BIOTHERAP
2014
Leon RecanatiEVOGENE LTD
2005
Philip SerlinKITOV PHARMA LTD
2013
Oded ShoseyovEVOGENE LTD
2018

Company Summary

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 89 people.COMPUGEN (CGEN) is traded on Tel Aviv Stock Exchange in Israel and employs 89 people.

COMPUGEN Leadership Team

Joshua Shemer, Independent External DirectorView
Michal Preminger, DirectorView
Paul Sekhri, Chairman of the BoardView
Dov Hershberg, DirectorView
Martin Gerstel, Chairman of the BoardView
Arie Ovadia, Independent External DirectorView
Zurit Levine, Vice President - Research and DiscoveryView
Eran Perry, DirectorView
Ari Krashin, Chief Financial OfficerView
Sanford Zweifach, DirectorView
Gilead Halevy, DirectorView
Anat CohenDayag, President, Chief Executive Officer, DirectorView
Ruth Arnon, Independent DirectorView
Kinneret Savitsky, DirectorView
Henry Adewoye, Chief Medical OfficerView
Yair Aharonowitz, Independent External DirectorView
JeanPierre Bizzari, DirectorView
John Hunter, VP of Antibody RandD and Site Head of Compugen USA IncView

Stock Performance Indicators

Current Sentiment - CGEN

COMPUGEN Investor Sentiment

Macroaxis portfolio users are unresponsive in their opinion about investing in COMPUGEN. What is your opinion about investing in COMPUGEN? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

COMPUGEN Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for COMPUGEN and KAMADA. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Please also try Money Flow Index module to determine momentum by analyzing money flow index and other technical indicators.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page